Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.
10.1097/CM9.0000000000001710
- Author:
Lin CAI
1
;
Jian-Zhong ZHANG
1
;
Min ZHENG
2
;
Shi-Fa ZHANG
3
;
Manmath PATEKAR
4
Author Information
1. Department of Dermatology, Peking University People's Hospital, Beijing 100044, China.
2. Department of Dermatology, Second Affiliated Hospital School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310.
3. Department of Dermatology, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110016, China.
4. Novartis Pharma AG, Basel, Switzerland.
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal, Humanized;
Arthritis, Psoriatic/drug therapy*;
China;
Humans;
Psoriasis/drug therapy*;
Severity of Illness Index;
Treatment Outcome
- From:
Chinese Medical Journal
2021;134(21):2629-2631
- CountryChina
- Language:English
